OREANDA-NEWS. January 30, 2012. Sinochem Group (Sinochem) and Royal DSM N.V. (DSM) signed a MOU to further explore cooperation opportunities in the field of Biotechnology building on the global strategic cooperation in Anti-Infectives, reported the press-centre of Sinochem.

Liu Deshu, President of Sinochem, Feike Sijbesma, Chairman of the Managing Board of DSM, Pan Zhengyi, Vice President of Sinochem, Stefan Doboczky, Member of the Managing Board of DSM, Jiang Weiming, Vice President of DSM and President of DSM China and Yang Lin, CFO of Sinochem attended the signing ceremony. Pan Zhengyi and Stefan Doboczky signed the MoU on behalf of both companies.

High-level meeting led by Liu Deshu and Feike Sijbesma was held before the signing ceremony. Both parties highly recognized the progress of DSP with shareholders' strong support and exchanged the common wishes for deepening mutual trust and further strategy partnership. During the meeting, extensive strategic cooperation possibly to be conducted were discussed.

The transaction of global anti-infectives business between DSM and Sinochem was completed on August 31st, 2011 and DSP was established as 50/50 joint venture then. DSP is the global market leader in ?-lactam antibiotics with world’s leading position in energy-saving, emission reduction, cleaner production and environmental protection. On December 9th, 2011, the groundbreaking ceremony for the construction of DSP’s newest production facility has taken place in Zibo of Shandong Province in China. The new plant will focus on the production and development of new Semi-Synthetic Cephalosporins (SSC) using proprietary biotechnology.